Course: SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine
CME Credits: 1.00
Released: 2021-08-06
The Pfizer/BioNTech (BNT162b2) SARS-CoV-2 mRNA vaccine demonstrated 95% efficacy after 2 doses during clinical trials. There are reports that individuals with previous SARS-CoV-2 infection elicit stronger antibody responses after 1 dose compared with individuals without prior infection.- Consequently, individuals with a documented prior COVID-19 infection may be sufficiently protected from reinfection after a single mRNA vaccine dose, which could free up availability of millions of additional doses. We evaluated the SARS-CoV-2 spike immunoglobin (Ig) G antibody levels after 1 and 2 BNT162b2 doses in previously infected individuals compared with those without previous infection.
Educational Objective
To identify the key insights or developments described in this article
View Full Course